BENZENO SHARON 4

What Happened
Sharon Benzeno, listed as Chief Commercial Ofc Imm Med (Chief Commercial Officer, Immune Medicine) at Adaptive Biotechnologies (ADPT), was granted 39,063 shares on 2026-03-04. The Form 4 reports the acquisition as an award/grant at $0.00 per share (total reported cash value $0), indicating a compensation issuance rather than an open-market purchase.

Key Details

• Transaction date: 2026-03-04; reported on Form 4 filed 2026-03-06 (Accession: 0001780854-26-000002).
• Transaction type/code: Grant/Award (code A).
• Shares acquired: 39,063; Price per share reported: $0.00; reported cash value: $0.
• Shares owned after transaction: Not specified in the filing.
• Footnotes/other: Filing does not specify whether these are RSUs, restricted stock, performance-based awards, or vesting/tax-withholding details.
• Timeliness: Form 4 was filed two days after the transaction date and appears timely under standard reporting rules.

Context
Grants and awards are typically part of executive compensation and do not necessarily signal immediate buying or selling intent. Because the filing lacks vesting or sale details, retail investors should treat this as a compensation event rather than a direct bullish or bearish insider trade.